The overall aim of this K24 Mid-Career Investigator Award in Patient-Oriented Research is to allow Dr. Frances Levin to continue to expand her programmatic line of clinical research and mentoring. Two main objectives drive the investigator's work: 1) develop pharmacotherapies that consider the heterogeneity of substance abusers and 2) provide mentorship to junior clinical investigators. Although there has been intensive investigation of medications and vaccines to treatment cocaine dependence, effective treatments remain elusive. Substance abuse is often accompanied with additional psychiatric comorbidity yet empirically-based treatments are limited. Moreover, there has been minimal research evaluating pharmacotherapies for cannabis use disorders, despite its substantial morbidity. Primary activities for this competing renewal and prior K24-funded accomplishments include developing novel combined medication treatment strategies for cocaine and cannabis-dependent individuals, testing new innovative behavioral interventions combined with pharmacotherapies for cocaine and other addictive disorders, and ensuring that promising human laboratory findings are efficiently tested in the outpatient treatment setting. During the course of this competing renewal K24 award Dr. Levin will be Principal Investigator of a U54 (a converted P50), a multi-site U1 (a converted R01), an R01, and Principal Investigator of a T32 that targets the training of physicians. Additionally, she will serve as a co-investigator or co-investigator on several other RO1s/R21s with both junior and mid-career colleagues that extend her areas of interest. And she will serve as a mentor on several mentored K awards. The career development plan for this application will expand Dr. Levin's knowledge into the areas of technology-based treatments, neuroimaging techniques, and stress-induced paradigms to predict treatment response through synergistic collaborations with other investigators. The mentoring plan incorporates trainees at various levels of development: 1) pre- doctoral trainees (medical students); 2) postdoctoral trainees (psychiatric residents and fellows); and 3) junior faculty. An overarching career goal has been to mentor clinical investigators and advance knowledge in the substance abuse field through reciprocal collaborations with other investigators, often with individuals that Dr. Levin has mentored or is currently mentoring. Of great public concern is a dearth of adequately trained physician investigators interested in clinical substance abuse research careers. Through Dr. Levin's activities it is hoped that the treatment of substance abusers will improve, both through her research and collaborations with colleagues, and through her training of the next generation of clinical investigators.

Public Health Relevance

The objectives of this patient-oriented K24 application is to gain greater knowledge of novel treatment options for substance use disorders. This goal addresses a critical public health need and will be attained through the investigator's programmatic line of patient-oriented research and Dr. Levin's mentorship of trainees and junior faculty such that they obtain the necessary research skills to pursue independent clinical research careers.

Agency
National Institute of Health (NIH)
Institute
National Institute on Drug Abuse (NIDA)
Type
Midcareer Investigator Award in Patient-Oriented Research (K24)
Project #
5K24DA029647-10
Application #
9751262
Study Section
Risk, Prevention and Intervention for Addictions Study Section (RPIA)
Program Officer
Aklin, Will
Project Start
2010-08-01
Project End
2020-07-31
Budget Start
2019-08-01
Budget End
2020-07-31
Support Year
10
Fiscal Year
2019
Total Cost
Indirect Cost
Name
Columbia University (N.Y.)
Department
Psychiatry
Type
Schools of Medicine
DUNS #
621889815
City
New York
State
NY
Country
United States
Zip Code
10032
Levin, Frances R; Cates-Wessel, Kathryn (2018) Commentary: Providing technical assistance for the state targeted response for opioid use disorders: Time is of the essence. Am J Addict 27:158-160
Brezing, Christina A; Choi, C Jean; Pavlicova, Martina et al. (2018) Abstinence and reduced frequency of use are associated with improvements in quality of life among treatment-seekers with cannabis use disorder. Am J Addict 27:101-107
Crunelle, Cleo L; van den Brink, Wim; Moggi, Franz et al. (2018) International Consensus Statement on Screening, Diagnosis and Treatment of Substance Use Disorder Patients with Comorbid Attention Deficit/Hyperactivity Disorder. Eur Addict Res 24:43-51
Brezing, Christina A; Levin, Frances R (2018) The Current State of Pharmacological Treatments for Cannabis Use Disorder and Withdrawal. Neuropsychopharmacology 43:173-194
Luo, Sean X; Wall, Melanie; Covey, Lirio et al. (2018) Exploring longitudinal course and treatment-baseline severity interactions in secondary outcomes of smoking cessation treatment in individuals with attention-deficit hyperactivity disorder. Am J Drug Alcohol Abuse 44:653-659
Notzon, Daniel P; Kelly, Meredith A; Choi, C Jean et al. (2018) Open-label pilot study of injectable naltrexone for cannabis dependence. Am J Drug Alcohol Abuse 44:619-627
Dakwar, E; Nunes, E V; Hart, C L et al. (2018) A sub-set of psychoactive effects may be critical to the behavioral impact of ketamine on cocaine use disorder: Results from a randomized, controlled laboratory study. Neuropharmacology 142:270-276
Levin, Frances R; Choi, C Jean; Pavlicova, Martina et al. (2018) How treatment improvement in ADHD and cocaine dependence are related to one another: A secondary analysis. Drug Alcohol Depend 188:135-140
Haney, Margaret; Cooper, Ziva D; Bedi, Gillinder et al. (2018) Guanfacine decreases symptoms of cannabis withdrawal in daily cannabis smokers. Addict Biol :
Martinez, Diana; Urban, Nina; Grassetti, Alex et al. (2018) Transcranial Magnetic Stimulation of Medial Prefrontal and Cingulate Cortices Reduces Cocaine Self-Administration: A Pilot Study. Front Psychiatry 9:80

Showing the most recent 10 out of 69 publications